Alpha DaRT alpha-particle therapy, key 2026 trial catalysts, cash/dilution risks, and M&A takeover potential. See more.

Alpha Tau Medical (NASDAQ:DRTS) provided investors with a series of clinical, regulatory and financial updates, highlighting ...

Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation alpha-emitting radioantibodies for the treatment of prostate cancer, today announced the appointment of ...

Trump Media is entering nuclear fusion via a $6B merger with TAE Technologies, aiming to create a publicly traded fusion ...

Scientists successfully transported a minute quantity of antimatter for the first time, opening up new possibilities for the ...

A new generation of nuclear microbatteries may soon power electronics that must operate for years without maintenance.

How did ancient fish perceive their environment in the deep sea? An international team led by scientists from the Natural ...

Lead program VMT-a-NET in neuroendocrine tumors continues to demonstrate a favorable tolerability profile with durable disease control and deepening of tumor response with longer follow-up, as reporte ...

NASA’s Curiosity rover accidentally split open a rock on Mars on May 30, 2024, exposing bright yellow crystals that turned ...

VMT-α-NET study on track to achieve nearly one year of follow-up in all 46 patients in Cohort 2 by mid-2026; analysis to inform patient selection strategy ongoing Data across all dose levels in the ...

High-energy particles called galactic cosmic rays (GCRs) bombard unprotected objects in space, often causing damage. Earth, ...

NASA outlines how Artemis II astronauts are monitored for solar particle events during their lunar mission, including spacecraft shielding, real-time tracking, and onboard radiation detection systems.